European Medicines Agency Committee for Medicinal Products for Human Use

what is the recent combination therapy with Ribociclib from novartis demonstrating potential strong efficacy in 1L metastatic breast cancer?

(Kisqali) combined with an aromatase inhibitor—most commonly letrozole—has emerged as a standout first‑line (1L) combination therapy for hormone‑receptor–positive (HR+), HER2‑negative metastatic breas...